Causes and consequences of the loss of serotonergic presynapses elicited by the consumption of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') and its congeners

Journal of Neural Transmission

Volumn 104, Issue 8-9, 1997, Pages 771-794

  Huether, G ^a,b   Zhou, D ^a   Ruther E ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

3,4 methylenedioxymethamphetamine; Degeneration; Ecstasy; MDMA; Neurotoxicity; Serotonin; Substituted amphetamines

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ADENOSINE TRIPHOSPHATE; AMPHETAMINE DERIVATIVE; NEUROTRANSMITTER; SEROTONIN;

ACTIVE TRANSPORT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BEHAVIOR DISORDER; CALCIUM HOMEOSTASIS; CONTROLLED STUDY; DETOXIFICATION; DOPAMINERGIC ACTIVITY; ENERGY METABOLISM; ENVIRONMENTAL TEMPERATURE; HUMAN; HYPERTHERMIA; INFORMATION PROCESSING; ION EXCHANGE; ION TRANSPORT; NERVE CELL NETWORK; NERVE ENDING; NERVE INJURY; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PERSONALITY; PRESYNAPTIC MEMBRANE; PRESYNAPTIC NERVE; PRIORITY JOURNAL; RAT; REVIEW; SEROTONIN RELEASE; SEROTONIN SYNDROME; SEROTONINERGIC NERVE; SEROTONINERGIC SYSTEM;

EID: 0030660459     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01285547     Document Type: Review

References (145)

1. Agrew H, Reibring L (1994) PET-studies of presynaptic monoamine metabolism in depressed patients and healthy volunteers. Pharmacopsychiat 27: 2-6
2. Allen RP, McCann UD, Ricaurte GA (1993) Persistent effects of (+)-3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") on human sleep. Sleep 16: 560-564
3. Ames D, Wirshin WC (1993) Ecstasy, the serotonin syndrome and neuroleptic malignant syndrome - a possible link? JAMA 269: 869
4. Axt KJ, Molliver ME (1991) Immunocytochemical evidence for methamphetamine-induced serotonergic axon loss in the rat-brain. Synapse 9: 302-313
5. Axt KJ, Commins DL, Vosmer G, Seiden LS (1990) α-methyl-p-tyrosine pretreatment partially prevents methamphetamine-induced endogenous neurotoxin formation. Brain Res 515: 269-276
6. Azmitia EC, Whitaker-Azmitia PM (1991) Awakening the sleeping giant; anatomy and plasticity of the brain serotonergic system. J Clin Psychiatry 52: 4-16
7. Azmitia EC, Frankfurt M, Davila M, Whitaker-Azmitia PM, Zhou F (1990a) Plasticity of fetal and adult CNS serotonergic neurons: role of growth-regulatory factors. Ann NY Acad Sci 600: 342-365
8. 2+-dependent toxicity linked to release. Brain Res 510: 97-103
9. 1A agonist and dexamethasone reversal of para-chloroamphetamine induced loss of MAP-2 and synaptophysin immunoreactivity in adult rat brain. Brain Res 677: 181-192
10. 3H]-paroxetine-labelled serotonin uptake sites. J Pharmacol Exp Ther 242: 911-916
11. Battaglia G, Brooks BP, Kulsakdinun C, De Souza EB (1988) Pharmacologic profile of MDMA (3,4-methylenedioxy-methamphetamine) at various brain recognition sites. Eur J Pharmacol 149: 159-163
12. Battaglia G, Sharkey J, Kuhar MJ, De Souza EB (1991) Neuroanatomic specificity and time course of alterations in rat brain serotonergic pathways induced by MDMA (3,4-methylenedioxymethamphetamine): assessment using quantitativ autoradiography. Synapse 8: 249-260
13. Bedford-Russel AR, Schwartz RH, Dawling S (1992) Accidental igestion "ecstasy" (3,4-methylenedioxymethamphetamine). Arch Dis Child 67: 1114-1115
14. Berger UV, Grzanna R, Molliver ME (1989) Depletion of serotonin using p-chlorophenylalanine (PCPA) and reserpine protects against the neurotoxic effects of p-chloroamphetamine (PCA) in the brain. Exp Neurol 103: 111-115
15. Berger UV, Grzanna R, Molliver ME (1990) Unlike systemic administration of PCA, direct intracerebral injection does not cause neurotoxicity on 5-HT axons. Exp Neurol 109: 257-268
16. Berger UV, Grzanna R, Molliver ME (1992a) The neurotoxic effects of p-chloroamphetamine in rat brain are blocked by prior depletetion of serotonin. Brain Res 578: 177-185
17. Berger UV, Gu XF, Azmitia EC (1992b) The substitued amphetamines 3,4-methylenedioxymethampethamine, methamphetamine, para-chloroamphetamine and fenfluramine induce 5-hydroxytryptamine relase via a common mechanism blocked by fluoxetine and cocaine. Eur J Pharmacol 215: 153-160
18. Bowyer JV, Davies DL, Schmued L (1994) Further studies of the role of hyperthermia in methamphetamine neurotoxicity. J Pharmacol Exp Ther 286: 1571-1580
19. Bradberry CW, Sprouse JS, Aghajanian GK, Roth RH (1990) 3,4-MDMA-induced release of endogenous serotonin from the rat dorsal raphe nucleus in vitro: effects of fluoxetine and tryptophan. Neurochem Int 17: 509-513
20. Brodkin J, Malyala A, Nash JF (1993) Effect of acute monoamine depletion on 3,4-methylenedioxymethamphetamine-induced neurotoxicity. Pharmacol Biochem Behav 45: 647-653
21. Broening HW, Bacon L, Slikker W jr (1994) Age modulates the long-term but not the acute effects of the serotonergic neurotoxicant 3,4-methylenediamphetamine. J Pharmacol Exp Ther 271: 285-293
22. Brown C, Osterloh J (1987) Multiple severe complications from recreational ingestion of MDMA ("Ecstasy"). J Am Med Assoc 258: 780-781
23. Brückner G, Biesold D (1981) Histochemistry of glycogen deposition in perinatal rat brain: importance of radial glial cells. J Neurocytol 10: 749-757
24. Chadwick IS, Linsley A, Freemont AJ, Doran B, Curry PD (1991) Ecstasy, 3,4-methylenedioxymethamphetamine (MDMA), a fataly associated with coagulopathy and hyperthermia. J Roy Soc Med 84: 371
25. Cheng L, Hamaguchi K, Ogawa M, Hamada S, Okado N (1994) pCPA reduces both monoaminergic afferents and non-monoaminergic synapses in the cerebral cortex. Neurosci Res 19: 111-115
26. Choi DW (1988) Calcium mediated neurotoxicity: relationship to specific channel types and role in ischemic damage. Trends Neurosci 11: 465-469
27. Choi DW, Rothman SM (1990) The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death. Annu Rev Neurosci 13: 171-182
28. Chu T, Kumagain Y, DiStefano EW, Cho AK (1996) Disposition of methylenedioxymethamphetamine and three metabolites in the brains of different rat strains and their possible roles in acute serotonin depletion. Biochem Pharmacol 51: 789-796
29. Clemens JA, Fuller RW, Perry KW, Sawyer BD (1978) Effects of p-chloroamphetamine on brain serotonin in immature rats. Comm Psychopharmacol 2: 11-16
30. Cohen RS (1995) Subjective reports on the effects of the MDMA ("ecstasy") experience in humans. Progr Neuropsychopharmacol Biol Psychiatry 19: 1137-1145
31. Colado MI, Green AR (1994) A study of the mechanism of MDMA ("Ecstasy")-induced neurotoxicity of 5-HT neurones using chlormethiazole, dizocilpine and other protective compunds. Br J Pharmacol 111: 131
32. Colado MJ, Green AR (1995) The spin trap reagent α-phenyl-N-tert-butyl nitrone prevents "ecstasy"-induced neurodegeneration of 5-hydroxytryptamine neurons. Eur J Pharmacol 280: 343-346
33. Colado MI, Murray TK, Green AR (1993) 5-HT loss in rat brain following 3,4-methylenedioxymethamphetamine (MDMA), p-chloroamphetamine and fenfluramine administration and effects of chlormethiazole and dizocilpine. Br J Pharmacol 108: 583-589
34. Colado MI, Williams JL, Green AR (1995) The hyperthermic and neurotoxic effects of "Ecstasy" (MDMA) and 3,4-methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metaboliser phenotype. Br J Pharmacol 115: 1281-1289
35. Commins DL, Axt KJ, Vosmer G, Seiden LS (1987) Endogenously produced 5,6-DHT may mediate the neurotoxic effects of para-chloroamphetamine. Brain Res 419: L253-261
36. Dafters RI (1994) Effects of ambient temperature on hyperthermia and hyperkinesis induced by 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy") in rats. Psychopharmacology 114: 505-508
37. Dafters RJ (1995) Hyperthermia following MDMA administration in rats: effects of ambient temperature, water consumption, and chronic dosing. Physiol Behav 58: 877-882
38. 2+ dynamics after toxic doses of glutamate in cerebellar granule cells. Proc Natl Acad Sci USA 87: 8017-8021
39. De Vito M, Wagner GC (1989) Methamphetamine-induced neuronal damage: a possible role for free radicals. Neuropharmacology 28: 1145-1150
40. Dowling GB, McDonough ET, Bost RO (1987) Eve and Ecstasy, a report of five deaths associated with the use of MDEA and MDMA. JAMA 257: 1615-1617
41. Eyre JA, Stuart AG, Forsyth Jr, Heaviside D, Bartlett K (1994) Glucose export from the brain in man: evidence for a role of astrocytic glycogen as a reservoir of glucose for neural metabolism. Brain Res 635: 349-352
42. Fahal IH, Sallomi DF, Yaqoob M, Bell GM (1992) Acute renal failure after ecstasy. BMJ 305: 29
43. Finnegan KT, Skratt JJÖ, Irwin I, Langston JW (1990) The N-methyl-D-aspartate (NMDA) receptor antagonist dextromethorphan prevents the neurotoxic effects of 3,4-methylenedioxymethamphetamine (MDMA) in rats. Neurosci Lett 105: 300-306
44. Friedman R (1993) Ecstasy, the serotonin syndrome and neuroleptic malignant syndrome - a possible link? JAMA 269: 869-870
45. Fuller RW (1980) Mechanisms by which uptake inhibitors antagonize p-chloroamphetamine-induced depletion of brain serotonin. Neurochem Res 5: 241-253
46. Fuller RW (1992) Effects of p-chloroamphetamine on brain serotonin neurons. Neurochem Res 17: 449-456
47. Gibb JW, Johnson M, Stone D, Hanson GR (1990) MDMA: historical perspectives. Ann NY Acad Sci 600: 601-611
48. Gledhill JA, Moore DF, Bell D, Henry JA (1993) Subarachnoid haemorrhage associated with MDMA abuse. J Neurol Neurosurg Psychiatry 56: 1036-1037
49. Gordon CJ, Wilkinson WP, O'Callaghan JP, Miller DB (1991) Effect of 3,4-methylenedioxymethamphetamine on autonomic thermoregulatory responses of the rat. Pharmacol Biochem Behav 38: 339-344
50. Grahame-Smith DG (1971) Studies in vivo on the relationship between brain tryptophan, brain 5-HT synthesis and hyperactivity in rats treated with monoamine oxidase inhibitor and L-tryptophan. J Neurochem 18: 1053-1066
51. Green AR, Heal DH (1985) The effects of drugs on serotonin-mediated behavioural models. In: Green AR (ed) Neuropharmacology of serotonin. Oxford University Press, pp 326-365
52. Green AR, Goodwin GM (1996) Ecstasy and neurodegeneration. Br Med J 312: 1493
53. Green AR, De Souza RJ, Williams JL, Murray TK, Cross AJ (1992) The neurotoxic effects of methamphetamine on 5-hydroxytryptamine and dopamine in brain: evidence for the protective effect of chlormethiazole. Neuropharmacol 31: 315-321
54. Green AR, Cross AJ, Goodwin GM (1995) Review of the pharmacology and clinical pharmacology of MDMA. Psychopharmacology 119: 247-260
55. Greer G, Tolbert R (1986) Subjective reports of the effects of MDMA in a clinical setting. J Psychoact Drugs 18: 319-327
56. Gu XF, Azmitia EC (1993) Integrative transporter-mediated release from cytoplasmic and vesicular 5-hydroxytryptamine stores in cultured neurons. Eur J Pharmacol 235: 51-57
57. Gudelsky GA (1996) Effect of ascorbate and cysteine on the 3,4-methylenedioxymethamphetamine-induced depletion of brain serotonin. J Neural Transm 103:1397-1404
58. Gudelsky GA, Nash JF (1996) Carrier-mediated release of serotonin by 3,4-methylenedioxymethamphetamine: implications for serotonin-dopamine interactions. J Neurochem 66: 243-249
59. 2 agonists. Eur J Pharmacol 264: 325-330
60. 3H]-paroxetine binding to rat cortical membranes. Eur J Pharmacol 118: 107-114
61. Hardman HF, Haavik CO, Seevers MH (1973) Relationship of the strsucture of mescaline and seven analogs to toxicity and behaviour in five species of laboratory animals. Toxicol Appl Pharmacol 25: 299-309
62. Harries DP, DeSilva R (1992) Ecstasy and intracerebral haemorrhage. Scot Med J 37: 150-152
63. Harvey JA, McMaster SE (1975) Fenfluramine: evidence for a neurotoxic action in midbrain and a long term depletion of serotonin. Pharmacol Commun 1: 217-228
64. Harvey JA, McMaster SE, Romano AG (1993) Methylenedioxyamphetamine: neurotoxic effects of serotonergic projections to brainstem nuclei in the rat. Brain Res 619: 1-14
65. Hekmatpanah CR, Peroutka SK (1990) 5-Hydroxytryptamine uptake blockers attenuate the 5-hydroxytryptamine releasing effect of 3,4-methylenedioxymethamphetamine and related agents. Eur J Pharmacol 177: 95-98
66. Henry JA (1996) Ecstasy and serotonin depletion. Lancet 347: 833
67. Henry JA, Jeffreys KJ, Dawling KS (1992) Toxicity and deaths from 3,4-methylenedioxyamphetamine ("ecstasy"). Lancet 340: 384-387
68. Hewitt KE, Green AR (1994) Chlormethiazole, dizocilpine and haloperidol prevent the degeneration of serotonergic nerve terminals induced by administration of MDMA ("Ecstasy"). Neuropharmacology 33: 1589-1595
69. Hirata H, Ladenheim B, Rothman RB, Epstein C, Cated JL (1995) Methamphetamine-induced serotonin neurotoxicity is mediated by superoxide radicals. Brain Res 677: 345-347
70. Hotchkiss A, Gibb JW (1980) Long term effects of multiple doses of methamphetamine on tryptophan hydroxylase and tyrosine hydroxylase in rat brain. J Pharmacol Exp Ther 214: 257-262
71. Hothershall JS, Greenbaum AL, McLean P (1982) The functional significance of the pentose phosphate pathway in synaptosomes: protection against peroxidative damage by catecholamines and oxidants. J Neurochem 39: 1325-1332
72. Insel TR, Battaglia G, Johanssen J, Marra S, De Souza EB (1989) 3,4-Methylenedioxymethamphetamine ("Ecstasy") selectively destroys brain serotonin nerve terminals rhesus monkeys. J Pharmacol Exp Ther 249: 713-720
73. Iyer RN, Sprouse JS, Aghajanian GK, Roth RH, Bradberry CW (1994) Tryptophan pretreatment augmentation of p-chloroamphetamine-incuded serotonine and dopamine release and reduction of long-term neurotoxicity. Biochem Pharmacol 48: 1501-1508
74. Jacobs BL, Fornal CA (1991) Activity of brain serotonergic neurons in the behaving animal. Pharmacol Rev 43: 563-578
75. Jacobs BL, Azmitia E (1992) Structure and function of the brain serotonin system. Physiol Rev 72: 165-229
76. Jacobs BL, Wilkinson LO, Fornal CA (1990) The role of brain serotonin. A neurophysiologic perspective. Neuropsychopharmacology 3: 473-479
77. Johnson MP, Elayan I, Hanson GR, Foltz RL, Gibb JW, Lim HK (1992) Effects of 3,4-dihydroxymethamphetamine and 2,4,5-trihydroxymethamphetamine, on central serotonergic and dopaminergic systems. J Pharmacol Exp Ther 261: 447-453
78. 3H]-Monoamine releasing and uptake inhibition properties of 3,4-methylenedioxymethamphetamine and p-chloroamphetamine analogues. Eur J Pharmacol 200: 9-16
79. Kapur S, Meyer J, Wilson AA, Houle S, Brown GM (1994) Modulation of cortical neuronal activity by a serotonergic agent: a PET study in humans. Brain Res 646:292-294
80. Karoum F, Chrapusta SJ, Egan MF, Wyatt RJ (1993) Absence of 6-hydroxydopamine in the rat brain after treatment with stimulants and other dopaminergic agents: a mass fragmentographic study. J Neurochem 61: 1369-1375
81. Kramer K, Poblete JCP, Azmitia EC (1995) 3,4-Methylenedioxymethamphetamine ("Ecstasy") promotes the translocation of protein kinase C (PKC): requirement of viable serotonin nerve terminals. Brain Res 680: 1-8
82. Kuikka JT, Tiihonen J, Bergström KA, Karhu J, Hartikainen P, Viinamäki H, Länsimies E, Lehtonen J, Hakola P (1985) Imaging of serotonin and dopamine transporters in the living human brain. Eur J Nucl Med 22: 346-350
83. Lauder JM (1990) Ontogeny of the serotonergic system in the rat: serotonin as developmental signal. Ann NY Acad Sci 600: 287-314
84. Lucot JB, Horwitz J, Seiden LS (1981) The effects of p-chloramphetamine administration on locomotor activity and serotonin in neonatal and adult rats. J Pharmacol Exp Ther 217: 738-744
85. Mamounas LA, Müllen CA, Ohearn E, Molliver ME (1991) Dual serotoninergic projections to forebrain in the rat - morphologically distinct 5-HT axon terminals exhibit differential vulnerability to neurotoxic amphetamine derivatives. J Comp Neurol 314: 558-586
86. Mann JJ, Malone KM, Diel DJ, Perel J, Cooper TB, Mintum MA (1996) Demonstration in vivo of reduced serotonin responsitivity in the brain of untreated depressed patients. Am J Psychiatry 153: 174-182
87. Marker H, Weiss C, Silides DJ, Cohen G (1981) Coupling of dopamine oxidation to glutathione oxidation via the generation of hydrogen peroxide in rat brain homogenates. J Neurochem 36: 589-593
88. McCann UD, Ricaurte GA (1991a) Lasting neuropsychiatrie sequelae of (+)-melthylenedioxymethamphetamine ("Ecstasy") in recreational users. J Clin Psychopharmacol 11: 302-305
89. McCann UD, Ricaurte GA (1991b) Major metabolites of 3,4-methylenedioxy-methamphetamine do not mediate its toxic effects on brain serotonin neurons. Brain Res 545: 279-282
90. McGuire PK, Cope H, Fahy TA (1994) Diversity of psychopathology associated with use of 3,4-methylenedioxymethamphetamine ("Ecstasy"). Br J Psychiatry 165: 391-395
91. Mesulam MM (1990) Large-scale neurocognitive networks and distributed processing for attention, language and memory. Ann Neurol 28: 597-613
92. 2O PET study in humans. Neurosci Lett 207: 25-28
93. Miller DB, O'Callaghan JP (1994) Environment and stress-induced alterations in body temperature affect of the neurotoxicity of substituted amphetamines in the C57BL/6J mouse. J Pharmacol Exp Ther 270: 752-760
94. Molliver ME, Berger UV, Mamounas LA, Molliver DL, O'Hearn E, Wilson MA (1990) Neurotoxicity of MDMA and related compunds: anatomic studies. Ann NY Acad Sci 600: 640-661
95. Nash JF (1990) Ketanserin pretreatment blocks MDMA-induced dopamine release in the striatum as measured by in vivo microdialysis. Life Sci 47: 2401-2408
96. Nash JF, Brodkin J (1991) Microdialysis studies on 3,4-methylenedioxymethamphetamine induced dopamine release: effect of dopamine uptake inhibitors. J Pharmacol Exp Ther 259: 820-825
97. Nichols DE (1986) Differences between the mechanisms of action of MDMA, MBDB, and the classic hallucinogens. Identification of a novel therapeutic class: entactogens. J Psychoact Drugs 18: 305-313
98. 3H]serotonin from rat brain synaptosomes. J Med Chem 25: 530-535
99. O'Hearn E, Battaglia G, De Souza EB, Kuhar MJ, Molliver ME (1988) Methylenedioxy-amphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity. J Neurosci 8: 2788-2803
100. Odell SJ, Weihmuller FB, Marshall JF (1991) Multiple methamphetamine injections induce marked increases in extracellular striatal dopamine which correlate with subsequent neurotoxicity. Brain Res 564: 256-260
101. Okado N, Cheng L, Tanatsugu Y, Hamada S, Hamaguchi K (1993) Synaptic loss following removal of serotonergic fibers in newly hatched and adult chickens. J Neurobiol 24: 687-698
102. Paris JM, 'Cunningham KA (1992) Lack of serotonin neurotoxicity after intraraphe microinjection of (+)-3,4methylenedioxymethamphetamine. Brain Res Bull 28: 115-119
103. ++-uptake into rat brain synaptosomes. Ann NY Acad Sci 635: 438-442
104. Passoneau JV, Lauderdale VR (1974) A comparison of three methods of glycogen measurement in tissues. Anal Biochem 60: 405-412
105. Pentreath VW, Seal LH, Morrison JH, Magistretti PJ (1986) Transmitter mediated regulation of energy metabolism in nervous tissue at the cellular level. Neurochem Int 9: 1-10
106. Peroutka SJ (1987) Incidence of recreational use of 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) on an undergraduate campus. N Engl J Med 317: 1542-1543
107. Peroutka SJ, Newman H, Harris H (1988) Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users. Neuropsychopharmacology 1:273-278
108. Pierce PA, Peroutka SJ (1988) Ring-substituted amphetamine interactions with neurotransmitter receptor binding sites in human cortex. Neurosci Lett 92: 208-212
109. Pierce PA, Peroutka SJ (1989) Hallucinogenic drug interactions with neurotransmitter receptor binding sites in human cortex. Psychopharmacol 97: 118-122
110. 2A-receptor. Brain Res 680: 9-15
111. Price LP, Ricaurte GA, Krystal JH, Heninger GR (1989) Neuroendocrine and mood response to L-tryptophan in 3,4-methylenedioxymethamphetamine (MDMA) users. Arch Gen Psychiatry 46: 20-22
112. Rhoades RW, Bennett Clarke CA, Chiaia NL, White FA, Macdonald GJ, Haring JM, Jacquin MF (1990) Development and lesion induced reorganization of the cortical representation of the rat's body surface as revealed by immunocytochemistry for serotonin. J Comp Neurol 293: 190-207
113. Ricaurte GA, McCann UD (1992) Neurotoxic amphetamine analogues: effects in monkeys and implications for humans. Ann NY Acad Sci 684: 371-382
114. Ricaurte G, Bryan G, Strauss L, Seiden L, Schuster C (1985) Hallucinogenic amphetamine selectively destroys brain serotonin terminals. Science 229: 986-988
115. Ricaurte GA, Delanney LE, Irwin I, Langston JW (1988a) Toxic effects of MDMA on central serotonergic neurons in the primate: importance of route and frequency of drug adminsitration. Brain Res 446: 165-168
116. Ricaurte GA, Forno LS, Wilson MA, De Lanney LE, Irwin I, Molliver ME, Langston JW (1988b) MDMA selectively damages central serotonergic neurons in the primate. JAMA 260:51-55
117. Ricaurte GA, Finnegan KT, Irwin I, Langston JW (1990) Aminergic metabolites in cerebrospinal fluid of humans previously exposed to MDMA: preliminary observations. Ann NY Acad Sci 600: 699-710
118. Ricaurte GA, Molliver ME, Martello MB, Katz JL, Wilson MA, Martello AL (1991) Dexfenfluramine neurotoxicity in brains of non-human primates. Lancet 338: 1487-1488
119. Rudnick G, Wall SC (1992) The molecular mechanisms of ecstasy [3,4-methylenedioxyamphetamine (MDMA)]. Serotonin transporters are targets for MDMA-induced serotonin release. Proc Natl Acad Sci USA 89: 1817-1821
120. Sanders-Bush E, Bushing JA, Sulser F (1972) p-Chloroamphetamine-inhibition of cerebral tryptophan hydroxylase. Biochem Pharmacol 21: 1501-1510
121. Schmidt CJ (1987) Neurotoxicity of the psychedelic amphetamine, methylenedioxmethylamphetamine. J Pharmacol Exp Ther 240: 1-7
122. Schmidt CJ, Ritter JK, Sonsalla PK, Hanson GR, Gibb JW (1985) Role of dopamine in the neurotoxic effects of methamphetamine. J Pharmacol Exp Ther 233: 539-544
123. Schmidt CJ, Black CK, Abbate GM, Taylor VL (1990a) Chloral hydrate anesthesia antagonizes the neurotoxicity of MDMA. Eur J Pharmacol 191: 213-218
124. 2-receptors. Brain Res 529: 85-90
125. 2-antagonists steroselectively prevent the neurotoxicity of 3,4-methylenedioxymethamphetamine, p-chloroamphetamine or methamphetamine to rats. Eur J Pharmacol 203: 41-49
126. Screaton GR, Singer M, Cairns HS, Thrasher A, Sarner M, Cohen SL (1992) Hyperpryrexia and rhabdomyolysis after MdMA ("Ecstasy") abuse. Lancet 339: 677-678
127. Seguela P, Watkins KC, Descarries L (1989) Ultrastructural relatinship of serotonin axon terminals in the cerebral cortex of the adult rat. J Comp Neurol 289: 129-142
128. Seiden JS, Vosmer G (1984) Formation of 6-hydroxydopamine in candate nucleus of rat brain after a single large dose of methamphetamine. Pharmacol Biochem Behav 21: 29-31
129. Seiden LS, Sabol KE, Ricaurte G (1993) Amphetamine effects on catecholamine systems and behavior. Annu Rev Pharmacol 32: 639-677
130. Shulgin AT (1986) The background and chemistry of MDMA. J Psychoact Drugs 18: 291-304
131. Sirvio J, Riekkinen P jr, Jakala P, Riekkinen PJ (1994) Experimental studies on the role of serotonin in cognition. Prog Neurobiol 43: 363-379
132. Slikker W Jr, Holson RR, Ali SF, Kolta MG, Paule MG, Scallet AC, McMillan DE, Bailey JR, Hong JS, Scalzo FM (1989) Behavioural and neurochemical effects of orally adminisstered MDMA in the rodent and nonhuman primate. Neurotoxicology 10: 529-542
133. Smale L, Michels KM, Morre RY, Morin LP (1990) Destruction of the hamster serotonergic system by 5,7-DHT: effects on circadian rhythm phase, intrainment and response to triazolam. Brain Res 515: 9-19
134. Spanos LJ, Yamamoto BK (1989) Acute and subchronic effects of methylenedioxymethamphetamine [(+)-MDMA] on locomotion and serotonin syndrome behaviour in the rat. Pharmacol Biochem Behav 32: 835-840
135. Spoont MR (1992) Modulatory role of serotonin in neural information processing: implications for human psychopathology. Psychol Bull 112: 330-350
136. Sprague J, Nichols DE (1995) The monoamine oxidase B inhibitor L-deprenyl protects against 3,4-methylenedioxymethamphetamine-induced lipid peroxidation and long-term serotonergic deficits. J Pharmacol Exp Ther 273: 667-673
137. Sternbach H (1991) The serotonin syndrome. Am Psychiat 148: 705-713
138. Stone DM, Stahl DC, Hanson GR, Gibb JW (1986) The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxymamphetamine (MDA) on monoaminergic systems in the rat brain. Eur J Pharmacol 128: 41-48
139. Stone DM, Johnson M, Hanson GR, Gibb JW (1988) Role of endogenous dopamine in the central serotonergid deficits induced by 3,4-methylenedioxymethamphetamine. J Pharmacol Exp Ther 247: 79-87
140. Stone DM, Hanson GR, Gibb JW (1989) In vitro reactivation of rat cortical tryptophan hydroxylase following in vivo inactivation by MDMA. J Neurochem 53: 572-581
141. Swanson RA, Choi DW (1993) Glial glycogen stores affect neuronal survival during glucose deprivation in vitro. J Cereb Blood Flow Metab 13: 162-169
142. 1A receptors releases the serotonergic growth factor, protein S100, and alters astroglial morphology. Brain Res 528: 155-158
143. Wilson MA, Ricaurte GA, Molliver ME (1989) Distinct morphologic classes of serotonergic axons in primates exhibit differential vulnerability to the psychotropic drug 3,4-methylenedioxymethamphetamine. Neuroscience 28: 121-137
144. Wing LL, Tapson GS, Geyer MA (1995) 5-HT-2 mediation of acute behavioral-effects of hallucinogens in rats. Psychopharmacology 100: 417-425
145. Zhou D, Schreinert M, Pilz J, Huether G (1996) Rat strain differences in the vulnerability of serotonergic nerve endings to neurotoxic damage by p-chloroamphetamine. J Neural Transm 103: 1381-1395